Study Enrollment


Your details will not be published or shared.

Clinical Trial

A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, FLEXIBLE-DOSE, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAVAPADON AS ADJUNCTIVE THERAPY FOR PARKINSONíS DISEASE IN LEVODOPA-TREATED ADULTS WITH MOTOR FLUCTUATIONS (TEMPO-3 TRIAL)

Cerevel has begun a study of an investigational drug called CVL-751, also known as Tavapadon, as a possible adjunctive treatment for Parkinsons disease. Tavapadon works by the dopamine system in the brain and is being investigated to see if it can further improve Parkinson Disease symptoms when taking levadopa.


Eligibility Criteria

  • Has been diagnosis Parkinsons Disease PD Patient is 40 to 80 years old

Contact Information

    Buff Farrow

    (706) 721-2798

   bfarrow@augusta.edu

RESEARCH. INNOVATION. DISCOVERY.